Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy

Jarrod Longcor; Natalie Callander; Kate Oliver; Asher Chanan-Khan; Sikander Ailawadhi

doi:10.1038/s41408-022-00725-2

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy

Jarrod Longcor, Natalie Callander, Kate Oliver, Asher Chanan-Khan, Sikander Ailawadhi

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	130
Journal	Blood cancer journal
Volume	12
Issue number	9
DOIs	https://doi.org/10.1038/s41408-022-00725-2
State	Published - Sep 2022

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-022-00725-2

Cite this

@article{4f0f4d911d0d456cbffaf2ea40bf903e,

title = "Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy",

author = "Jarrod Longcor and Natalie Callander and Kate Oliver and Asher Chanan-Khan and Sikander Ailawadhi",

note = "Funding Information: This study was supported by Cellectar Biosciences and the National Institute of Health (SBIR grant HHSN261201500071C). ",

year = "2022",

month = sep,

doi = "10.1038/s41408-022-00725-2",

language = "English (US)",

volume = "12",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy

AU - Longcor, Jarrod

AU - Callander, Natalie

AU - Oliver, Kate

AU - Chanan-Khan, Asher

AU - Ailawadhi, Sikander

N1 - Funding Information: This study was supported by Cellectar Biosciences and the National Institute of Health (SBIR grant HHSN261201500071C).

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85137314802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137314802&partnerID=8YFLogxK

U2 - 10.1038/s41408-022-00725-2

DO - 10.1038/s41408-022-00725-2

M3 - Letter

C2 - 36068232

AN - SCOPUS:85137314802

SN - 2044-5385

VL - 12

JO - Blood cancer journal

JF - Blood cancer journal

IS - 9

M1 - 130

ER -

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this